Sai Parenterals’ Rs 409 crore IPO is set for a flat debut with a 0% grey market premium, reflecting subdued investor sentiment and weak retail subscription. Despite a diversified pharma business and expansion plans, aggressive valuations at over 70 times P/E appear to have deterred individual investors, though institutional participation helped the issue scrape through.
Recent Posts
- Eternal Shares Preferred Over Peers As HDFC Securities Upgrades Rating — Check Target Price
- Dhurandhar 2 Box Office Collection, Day 14: Ranveer Singh, Sanjay Dutt Starrer Crosses Rs 1,460 Crore Worldwide
- Stocks to buy or sell: Osho Krishan of Angel One suggests buying Hindustan Zinc, Chennai Petroleum shares to buy
- ₹1.22 lakh crore outflows! Is retail investors’ love for SIPs giving FIIs an easy exit route amid market turmoil?
- Sensex crashes 1500 points, investors lose ₹9 lakh crore after Trump’s speech— Key factors behind market fall explained